Aligos Therapeutics Stock Performance
| ALGS Stock | USD 10.75 0.77 6.68% |
The firm shows a Beta (market volatility) of 3.34, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aligos Therapeutics will likely underperform. At this point, Aligos Therapeutics has a negative expected return of -1.81%. Please make sure to confirm Aligos Therapeutics' maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Aligos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Aligos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (6.68) | Five Day Return (6.44) | Year To Date Return (73.00) | Ten Year Return (97.10) | All Time Return (97.10) |
Last Split Factor 1:25 | Last Split Date 2024-08-19 |
1 | Drive Wealth Management LLC Takes 916,000 Position in Aligos Therapeutics, Inc. - MarketBeat | 01/27/2025 |
2 | Aligos Therapeutics Announces 105 Million Private Placement Financing | 02/12/2025 |
3 | Acquisition by Quan Lucinda Y. of 48000 shares of Aligos Therapeutics at 0.84 subject to Rule 16b-3 | 02/18/2025 |
4 | Acquisition by Blatt Lawrence of 965435 shares of Aligos Therapeutics at 1.13 subject to Rule 16b-3 | 02/21/2025 |
5 | UniQure Reports Q4 Loss, Misses Revenue Estimates | 02/27/2025 |
6 | Acquisition by Calhoun Lesley Ann of 47271 shares of Aligos Therapeutics at 16.87 subject to Rule 16b-3 | 02/28/2025 |
7 | Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 | 03/03/2025 |
8 | Acquisition by Blatt Lawrence of 140103 shares of Aligos Therapeutics at 16.87 subject to Rule 16b-3 | 03/04/2025 |
9 | Acquisition by Symons Julian A. of 78750 shares of Aligos Therapeutics at 1.34 subject to Rule 16b-3 | 03/07/2025 |
10 | Aligos Therapeutics GAAP EPS of -13.08 misses by 10.58 | 03/10/2025 |
11 | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 03/14/2025 |
| Begin Period Cash Flow | 135.8 M |
Aligos |
Aligos Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,885 in Aligos Therapeutics on December 22, 2024 and sell it today you would lose (2,810) from holding Aligos Therapeutics or give up 72.33% of portfolio value over 90 days. Aligos Therapeutics is currently does not generate positive expected returns and assumes 7.3687% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Aligos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aligos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aligos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aligos Therapeutics, and traders can use it to determine the average amount a Aligos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2455
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALGS |
Estimated Market Risk
| 7.37 actual daily | 65 65% of assets are less volatile |
Expected Return
| -1.81 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aligos Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aligos Therapeutics by adding Aligos Therapeutics to a well-diversified portfolio.
Aligos Therapeutics Fundamentals Growth
Aligos Stock prices reflect investors' perceptions of the future prospects and financial health of Aligos Therapeutics, and Aligos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aligos Stock performance.
| Return On Equity | -4.16 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (32.69) % | ||||
| Current Valuation | 17.23 M | ||||
| Shares Outstanding | 5.31 M | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 17.84 X | ||||
| Revenue | 3.94 M | ||||
| Gross Profit | (66.32 M) | ||||
| EBITDA | (89.15 M) | ||||
| Net Income | (131.21 M) | ||||
| Cash And Equivalents | 159.34 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 8.38 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 5.30 X | ||||
| Book Value Per Share | (7.50) X | ||||
| Cash Flow From Operations | (80.74 M) | ||||
| Earnings Per Share | (20.94) X | ||||
| Market Capitalization | 70.37 M | ||||
| Total Asset | 70.09 M | ||||
| Retained Earnings | (618.01 M) | ||||
| Working Capital | 40.4 M | ||||
About Aligos Therapeutics Performance
Assessing Aligos Therapeutics' fundamental ratios provides investors with valuable insights into Aligos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aligos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.87) | (1.78) | |
| Return On Capital Employed | (1.84) | (1.75) | |
| Return On Assets | (1.87) | (1.78) | |
| Return On Equity | 4.53 | 4.76 |
Things to note about Aligos Therapeutics performance evaluation
Checking the ongoing alerts about Aligos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aligos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aligos Therapeutics generated a negative expected return over the last 90 days | |
| Aligos Therapeutics has high historical volatility and very poor performance | |
| Aligos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (66.32 M). | |
| Aligos Therapeutics currently holds about 159.34 M in cash with (80.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Latest headline from finance.yahoo.com: Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing Aligos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aligos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aligos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aligos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aligos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aligos Therapeutics' stock. These opinions can provide insight into Aligos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.